Combination of a polyamine-free oral nutritional supplement (ONS) with docetaxel in castrate-resistant prostate cancer (CRPC) patients (pts): A phase II trial.
- Xavier Artignan,
- Laurent Miglianico,
- Dominique Bligny,
- Christine Abraham,
- Jacques Philippe Moulinoux,
- Bernard Cipolla
J Clin Oncol 2012 Feb;30(5_suppl):67
CH Privé Saint Grégoire, Saint Gregoire, France; Oncologie Hematologie Radiotherapie, Saint Gregoire, France; CH Mignot, Le Chesnay, France; Université Rennes 1, GRETAC, Rennes, France.
67 Background: Polyamines (PA) are essential for cancer cell growth. Reducing exogenous PA (foods + gut flora) and blocking PA synthesis, reduces tumour growth and potentializes chemotherapy in rodent tumour models. We have developed a PA "free" ONS, which inhibits tumour growth by 40% in pre-clinical models and assessed its tolerance with docetaxel in CRPC pts. Read More